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Clinical Evaluation of Indoramin as the Sole
Agent for the Treatment of Hypertension
R. KRAMER, C. ROSENDORFF, D. BLOOM
TABLE I. STANDING DIASTOLlC BLOOD PRESSURE,
PRETREATMENT, AFTER 2 WEEKS OFF ALL
ANTIHYPERTENSIVE THERAPY
were females and 8 were males. All antihypertensive
therapy was stopped for 2 weeks to establish basal or
pretreatment blood pressures (Table 1) and pulse rates,
and also to determine the severity of hypertension.
SUMMARY
An open-ended clinical trial of Indoramin (WY-21901), a
new antihypertensive agent with both a-adrenergic block-
ing and cardio-inhibitory properties, was conducted on a
group of 27 patients with mild or moderate essential
hypertension. Blood pressures, erect and supine, were
effectively lowered. In 70% of the patients the mean stand-
ing diastolic pressures were well controlled. Heart rate
was not significantly lowe.red. Side-effects occurred in
80% of patients, but did not persist in most of them.
Severe side-effects, necessitating withdrawal of Indoramin,
were experienced by one-third of the patients.
Proteinuria was observed in 3 patients and a slightly
elevated serum urea in 1. No other biochemical tests
were abnormal.

















drochloride, (WY-21901), is a new, oral antihypertensive
agent. In animals it has been shown to act by competitive
a-adrenergic receptor blockade' and by reducing the rate
and force of myocardial contraction.,,2 The latter action
is thought to be due to a local anaesthetic or lignocaine-
like effect on the myocardium. The possibility that Indo-
ramin might simultaneously modify two of the mechanisms
involved in blood pressure control, viz. cardiac output
and peripheral resistance, led to its investigation in healthy
human subjects in whom it lowered blood pressure in the
supine and standing positions'" without significantly
affecting cardiac output or heart rate.
In this article the efficacy and side-effects of Indoramin
as the sole therapeutic agent in the treatment of essential
hypertension are reported.
PATIENTS AND METHODS
Twenty-seven patients with essential hypertension were
selected from those attending the outpatients' clinic at
the Johannesburg General Hospital. (The purpose of
the trial was explained to each patient and their informed
consent obtained.) The mean age was 61,8 years. Nineteen
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The severity of hypertension was classified as mild,
moderate or severe, according to an index derived from
the blood pressure, optic fundi, electrocardiogram, chest
X-ray- film, urinalysis, serum urea and cerebrovascular
history! No patients in this series had severe hypertension
by these criteria. Secondary hypertension was excluded
by clinical examination, by testing the urine for protein,
cells and bacteria (colony count), intravenous pyelography
and the measurement of 24-hour urinary vanillylmandelic
acid excretion. Serum urea, Na+, K+, Cl-, HCO-3, uric acid
and random glucose levels were determined. Chest X-ray
films and electrocardiograms were taken.
Patients were seen at the same time of the day, by the
same investigator, at weekly intervals. At each visit blood
pressure and pulse were recorded in the recumbent
position after the patient had been supine for at least
3 minutes, and in the standing position 1 minute after
rising. (Blood pressures were measured with a Hawksley
random zero sphygrnomanometer: to minimise observer
bias and digit preference.) At each visit, the patients were
questioned about headache, dizziness, tiredness, insomnia,
palpitations or any other symptoms. Symptoms were
graded by the patient as mild, moderate or severe. In the
third week Indoramin was started at a dose of 60 mg/day
(in 3 divided doses). The dose was progressively increased
each week until the blood pressure became stabili~ed at
a satisfactory level (i.e. standing diastolic blood pressure
less than 100 mrnHg); or until side-effects precluded further
increases or warranted withdrawal of the drug. In each
case, the trial was terminated after 3 successive weeks
of satisfactory blood pressure, or if side-effects prevented
1570 S.-A. MEDIESE TYDSKRIF 3 Augustus 1974
40 80 120 160 200 240 280 300





















* For criteria of control, see text. MSDP
pressure.
dose in mgj day
mean dose: 150 mgjday
TABLE Ill. EFFICACY OF INDORAMIN AS THE SOLE AGENT
IN THE TREATMENT OF ESSENTIAL HYPERTENSION (27
PATIENTS)
Laboratory Investigations
increases in dosage. The mean duration of therapy was
7,9 weeks.
At the end of the pretreatment and trial periods the
following were determined: protein in urine; haemoglobin,
packed cell volume, mean corpuscular haemoglobin con-
centration, white cell count (total and differential); serum
urea, sodium, potassium, chloride, bicarbonate, uric acid.
serum glutamic oxaloacetic and glutamic pyruvic trans-
aminases, alkaline phosphatase, bilirubin, albumin, globu-
lin; and direct Coombs test.
The assessment f blood pressure control used in this
article is that of Atbanassiadis et at,' based on the mean
standing diastolic pressure (MSDP) over the final 3 weeks
of treatment, as follows:
Good control: MSDP of 100 mmHg or less, or at least
41 mmHg below pretreatment levels.
Fair control: MSDP of 101 - 110 mmHg or 21 - 40
mmHg below pretreatment levels.
Poor control: MSDP of over 110 mmHg but 11 - 20
mmHg below pretreatment levels;
Failed control: MSDP not significantly different from
pretreatment levels.
The percentage change in blood pressure and heart
rates between the pretreatment and the final values was
calculated, and probability (P) was determined from




The doses administered at the end of the trial are
shown in Fig. I.
was 'good' or 'fair' in 19 of the 27 patients (70%). Table
!V shows the mean fall in blood pressure as a percentage
in these 19 patients. In 8 patients (30%) control was poor
or absent. In 3 of 8 the MSDP rose.
Control of Blood Pressure Heart Rate
IndoramiD was found to lower the mean blood pressure
of the group from 200/115 mmHg to 179/103 mmHg
supine, and from 185/114 mmHg to 160/99 mmHg standing.
Table II shows the mean fall in blood pressure expressed
as a percentage of the pretreatment blood pressure.
The efficacy of Indoramin in treatment of hypertension
is shown in Table Ill. Thus control of blood pressure
The mean recumbent heart rate was reduced from 78,3
to 71,1 beats per minute. In 12 patients it was unchanged
or rose. In the erect position the mean rate fell from 85, I
to 80,8 beats per minute, being unchanged or elevated in
14 patients. The bradycardia on Indoramin was not statis-
tically significantly different from pretreatment heart rate
(Table V).
TABLE 11. MEAN FALL IN flOOD PRESSURE ON INDORAMIN THERAPY (ALL PATIENTS)
Blood pressure (mmHg) Percentage fall
of blood Standard error
Off therapy On Indoramin pressure of mean
Supine BP
Systolic 200 179 8,9 3,1 P<o,o1
Diastolic 115 103 11,3 2,7 P<o,oOl
Standing BP
Systolic 185 160 13,2 3,7 P<o,o05
Diastofic ... 114 99 11,2 2,7 P<o,o01
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TABLE IV. MEAN FALL IN BLOOD PRESSURE OF PATIENTS WHO RESPONDED TO INDORAMIN
Blood pressure (mmHg) Percentage fall
of blood Standard error
Off therapy On Indoramin pressure of mean
Supine BP
Systolic 209 171 13,3 2,3 P<O,OOl
Diastolic 119 101 17,7 1,7 P<O,OOl
Standing BP
Systolic 189 153 17,4 2,8 P<O,OOl
Diastolic '.' 118 96 17,6 1,6 P<O,OOl
TABLE V. MEAN FALL IN HEART RATE (PERCENTAGE OF




Supine 4,4 2,5 P<O,l } NotStanding 2,2 2,8 P<O,5 significant
Side-Effects (Table VI)
Side-effects were reported by 22 patients (80%), but
most were occasional or transient. The n.'·st common
persistent side-effects were tiredness, nasal stuffiness and
dry mouth. The most severe side-effect was tiredness.
Indoramin had to be stopped in 9 patients (33 ~!,) because
of severe side-effects (tiredness in 6 patients, dizziness in
2, nasal stuffiness in 3 and impotence which reversed 6
weeks later in 1 patient). Note that in some cases more
than one severe side-effect was present. Table VII shows
that the side-effects were more or less evenly distributed
between the patients who responded to Indoramin and
those who did not. Three patients were depressed while
on treatment; we were, however, unable to assess whether
this was linked to Indoramin or not.
Laboratory Investigations
In 2 patients a trace of protein appeared in the
urine; proteinuria had been absent in both in the pre-
TABLE VI. SIDE-EFFECTS OF INDORAMIN THERAPY (27 PATIENTS)
Severity Duration
No. of Transient or
Side-effect patients Mild Moderate Severe occasional Persistent
Tiredness 15 2 8 5 9 6
Nasal stuffiness 9 2 4 3 6 3
Dry mouth 4 2 1 1 1 3
Dizziness 8 3 4 1 6 2
Impotence 1 0 0 1 0 1
Insomnia 3 1 1 1 3 0
40 10 18 12 25 15
No. of patients with one or more side· effects = 22 = 80%. Indoramin stopped because of side-effects in 9 (33%) patients.
TABLE VII. COMPARISON OF INCIDENCE OF SIDE-EFFECTS BETWEEN PATIENTS WHO RESPONDED TO INDORAMIN
('GOOD' OR 'FAIR' CONTROL) AND THOSE WHO DID NOT RESPOND ('POOR' OR 'FAILED' CONTROL)
Severity of responders Severity of non-responders
(19 patients) (8 patients)
Side-effect No. Mild Mod. Severe No. Mild Mod. Severe
Tiredness 10 2 5 3 5 0 3 2
Nasal stuffiness 7 2 3 2 2 0 1 1
Dry mouth 1 1 0 0 3 2 0 1
Dizziness 6 2 3 1 2 1 1 0
Impotence 1 0 0 1 0 0 0 0
Insomnia 1 0 0 1 2 1 1 0
26 7 11 8 14 4 6 4
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treatment period. One did not respond to Indoramin; his
blood pressure had, in fact, risen. The other was a woman
with a serum urea of 54 mg/IOO ml before and 50 mg/IOO
ml after treatment with Indoramin. After cessation of
therapy the proteinuria disappeared in both. One male
developed a '2 +' proteinuria, but did not return for follow-
up. In 1 woman the serum urea rose from 34 to 50
mg/IOO m!. No other biochemical abnormalities were
detected in any patient. Haematological and liver function
tests remained within normal limits. In no instance was
the Coombs test positive.
DISCUSSION
Indoramin was effective in lowering the blood pressure of
hypertensive patients, control being good or fair in 70%.
Side-effects were observed in 22 of 27 patients studied
(80%). The incidence of side-effects would probably have
been lower if diuretics or other hypotensive therapy had
been added, as is common medical practice.
In order to evaluate this drug fairly, it is desirable to com-
pare it with other antihypertensive agents. However, one
should be cautious in comparing drugs from dJlerent trials
as (a) patient groups may not be identical; (b) diuretics
are often used, allowing a lower dosage of therapeutic
agent and hence fewer side-effects; and (c) the method
of eliciting and scoring side-effects may differ. However,
some comparison may be made with alpha-methyldopa,
one of the few antihypertensive agents which has been
thoroughly documented in this regard.
Efficacy
Johnson et al.7 found that blood pressure control was
good or fair in 85 of 100 patients treated with
methyldopa for a mean period of 15,7 months, but had
to be discontinued in an additional 14 patients. The
diuretic chlorthalidone was also administered to 34 of the
100, but the trial included many patients with severe
hypertension who might have been excluded from our
trial. In 34 patients with benign essential hypertension,'
treated with methyldopa alone, good or fair control was
recorded in 85%.
Side-Effects
It is difficult to compare the precise incidence and
severity of side-effects because drugs are somewhat differ-
ent in action and are tolerated in varying degrees by
individual patients. In this study leading questions were used
to elicit side-effects, and it is likely that this technique
will overestimate the incidence of these side-effects. With
this reservation, it is clear that the incidence of side-effects
in our trial (80%) is similar to that reported in the study on
methyldopa (75% of l14 patients). However, the side-
effects were severe enough to necessitate withdrawal of
Indoramin in one-third of all our patients, compared with
only 17% of those on methyldopa. This may represent
a greater severity of side-effects, or may reflect a greater
sensitivity to these effects on the part of our patients or
investigators, or both. A larger, comparative, study is
planned to answer these and similar questions.
It is noteworthy that tachycardia was unusual with
Indoramin in contrast to other a-adrenoceptor blocking
agents.
The reversible proteinuria found in 3 patients and
the slightly raised serum urea in 1, may be due to
the drug, or may be part of the natural history of
hypertensive renal disease, or be unrelated to both. At
this stage in the assessment of this drug it seems wise,
however, to suggest that renal failure may be a contra-
indication to the use of lndoramin, and to suggest that
urinalysis and serum urea estimations be performed
frequently during its use.
We thank Wyeth Laboratories (Pty) Ltd for supporting this
study.
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